DALLAS, January 11, 2013 /PRNewswire/ -- The report "Metabolomics (Biomarker Discovery/Metabolite Detection/Metabolite Profiling) Market By Applications (Drug Discovery/Toxicology Assessment/ Diagnosis) and Indications (Oncology/Cardiology/Neurology)-Forecasts from 2012 to 2017", analyses the global metabolomics market by region, applications and indications with five year revenue forecasts. It also identifies the factors driving and restraining the global metabolomics market with analysis of trends, opportunities and challenges. The market is segmented and the revenue is forecasted on the basis of major regions such as America, Europe, Asia and Rest of the World (ROW) covering the key countries for each region. Further, the market is also segmented and revenues are forecasted on the basis of applications and disease indications. Browse11 market data tables and 36 figures spread through136 slidesand in-depth TOC on "Metabolomics (Biomarker Discovery/Metabolite Detection/Metabolite Profiling) Market By Applications (Drug Discovery/Toxicology Assessment/ Diagnosis) and Indications (Oncology/Cardiology/Neurology)-Forecasts from 2012 to 2017"http://www.marketsandmarkets.com/Market-Reports/metabolomics-technology-market-900.htmlEarly buyers will receive 10% customization on reports. In the post genomic era, metabolomics is gaining importance as another promising "omic" technology for understanding the biology of various diseases. Rapid advancement has been occurring in prediction, detection, monitoring and understanding of various diseases using metabolomic technologies. The market for metabolomic data analysis tools and software is increasing at a higher rate. Metabolomics allows pharma companies to stretch their R&D efforts by improving efficiency in target discovery and validation, mode-of-action, and toxicology studies. There has been a significant global growth in biotechnology and pharmaceutical industries in the last decade and the market is expected to have a double-digit growth rate in the coming years.